JP2021530992A5 - - Google Patents
Info
- Publication number
- JP2021530992A5 JP2021530992A5 JP2021500881A JP2021500881A JP2021530992A5 JP 2021530992 A5 JP2021530992 A5 JP 2021530992A5 JP 2021500881 A JP2021500881 A JP 2021500881A JP 2021500881 A JP2021500881 A JP 2021500881A JP 2021530992 A5 JP2021530992 A5 JP 2021530992A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- monomer
- antigen
- domain monomer
- polypeptide
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696673P | 2018-07-11 | 2018-07-11 | |
| US62/696,673 | 2018-07-11 | ||
| PCT/US2019/041438 WO2020014505A2 (en) | 2018-07-11 | 2019-07-11 | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530992A JP2021530992A (ja) | 2021-11-18 |
| JP2021530992A5 true JP2021530992A5 (https=) | 2022-07-20 |
| JPWO2020014505A5 JPWO2020014505A5 (https=) | 2022-07-20 |
Family
ID=69141701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500881A Withdrawn JP2021530992A (ja) | 2018-07-11 | 2019-07-11 | 改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210317227A1 (https=) |
| EP (1) | EP3820518A4 (https=) |
| JP (1) | JP2021530992A (https=) |
| KR (1) | KR20210043582A (https=) |
| CN (1) | CN113382749A (https=) |
| AU (1) | AU2019301684A1 (https=) |
| BR (1) | BR112021000415A2 (https=) |
| CA (1) | CA3106242A1 (https=) |
| IL (1) | IL280044A (https=) |
| MX (1) | MX2021000280A (https=) |
| WO (1) | WO2020014505A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4225787A4 (en) * | 2020-05-21 | 2024-10-23 | Zydus Lifesciences Limited | FC VARIANT AND PRODUCTION THEREOF |
| EP4178615A4 (en) * | 2020-07-10 | 2024-07-24 | Biomolecular Holdings LLC | TETRAHEDRAL ANTIBODIES |
| EP4273161A4 (en) * | 2020-12-31 | 2025-04-02 | Innovent Biologics (Suzhou) Co., Ltd. | Protein with heterodimeric antibody FC and manufacturing method therefor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101835802B (zh) * | 2007-06-01 | 2014-04-09 | 马里兰大学巴尔的摩分校 | 免疫球蛋白恒定区Fc受体结合剂 |
| EP2409989A1 (en) * | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Method to improve glycosylation profile for antibody |
| EP2748197A2 (en) * | 2011-08-26 | 2014-07-02 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| JP2015527366A (ja) * | 2012-08-20 | 2015-09-17 | グリックニック インコーポレイテッド | 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子 |
| KR20200024345A (ko) * | 2013-01-10 | 2020-03-06 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| JP2017518965A (ja) * | 2014-05-02 | 2017-07-13 | モメンタ ファーマシューティカルズ インコーポレイテッ | エンジニアリングされたＦｃ構築物に関連する組成物および方法 |
| WO2017044699A1 (en) * | 2015-09-10 | 2017-03-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 chimeric antigen receptors |
| WO2017151971A2 (en) * | 2016-03-02 | 2017-09-08 | Momenta Pharmaceuticals, Inc. | METHODS RELATED TO ENGINEERED Fc CONSTRUCTS |
| BR112018074056A2 (pt) * | 2016-05-23 | 2019-03-06 | Momenta Pharmaceuticals, Inc. | composições e métodos relacionados a construtos de fc manipulados |
| CA3043251A1 (en) * | 2016-12-09 | 2018-06-14 | Gliknik Inc. | Methods of treating inflammatory disorders with multivalent fc compounds |
| RU2019124709A (ru) * | 2017-01-06 | 2021-02-08 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА |
-
2019
- 2019-07-11 CN CN201980059592.5A patent/CN113382749A/zh active Pending
- 2019-07-11 JP JP2021500881A patent/JP2021530992A/ja not_active Withdrawn
- 2019-07-11 EP EP19833960.8A patent/EP3820518A4/en not_active Withdrawn
- 2019-07-11 US US17/259,443 patent/US20210317227A1/en not_active Abandoned
- 2019-07-11 CA CA3106242A patent/CA3106242A1/en active Pending
- 2019-07-11 MX MX2021000280A patent/MX2021000280A/es unknown
- 2019-07-11 BR BR112021000415-7A patent/BR112021000415A2/pt not_active IP Right Cessation
- 2019-07-11 WO PCT/US2019/041438 patent/WO2020014505A2/en not_active Ceased
- 2019-07-11 KR KR1020217004250A patent/KR20210043582A/ko not_active Withdrawn
- 2019-07-11 AU AU2019301684A patent/AU2019301684A1/en not_active Abandoned
-
2021
- 2021-01-10 IL IL280044A patent/IL280044A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7566766B2 (ja) | 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体 | |
| Kipriyanov et al. | Generation and production of engineered antibodies | |
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| US10519234B2 (en) | NKp46 binding proteins | |
| AU2025202388A1 (en) | CD3-targeting antibody, bispecific antibody and use thereof | |
| WO2015063187A1 (en) | Multivalent antigen-binding proteins | |
| US20210253736A1 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
| KR20200085828A (ko) | 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체 | |
| JPWO2019129221A5 (https=) | ||
| US20140308285A1 (en) | Heterodimeric bispecific antibodies | |
| JP2024511319A (ja) | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 | |
| JP2021526820A (ja) | 癌治療のための抗ｏｘＭＩＦ／抗ＣＤ３抗体 | |
| JP2017536341A (ja) | 卵巣がんの処置における使用のためのＣＤ３εおよびＲＯＲ１に対する二特異性抗体 | |
| JP2014522644A (ja) | 多重特異性抗体 | |
| RU2013142600A (ru) | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы | |
| CA3139508A1 (en) | Materials and methods for modulating t cell mediated immunity | |
| CN113150156B (zh) | 抗tigit抗体及其用途 | |
| JP2021530992A5 (https=) | ||
| US20230279108A1 (en) | Therapeutic sirp-alpha antibodies | |
| US20180371088A1 (en) | TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY | |
| US20240034815A1 (en) | Heterodimeric antibodies that bind cd3 and gpc3 | |
| US20180371089A1 (en) | Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecific antibody and uses thereof in caner therapy | |
| JP2026027248A (ja) | 抗原結合分子およびその使用 | |
| JPWO2021170068A5 (https=) | ||
| JPWO2020014505A5 (https=) |